Co-Authors
This is a "connection" page, showing publications co-authored by Andy Goren and Flavio Cadegiani.
Connection Strength
4.480
-
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021 Feb 22; 13(2):e13492.
Score: 0.931
-
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus. 2021 Feb 01; 13(2):e13047.
Score: 0.927
-
The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. Cureus. 2021 Jan 07; 13(1):e12565.
Score: 0.923
-
Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Front Med (Lausanne). 2020; 7:453.
Score: 0.895
-
SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study. Ann Thyroid. 2022 Mar; 6.
Score: 0.234
-
Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 01; 146:110439.
Score: 0.229
-
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses. 2020 Oct; 143:110112.
Score: 0.223
-
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021; 8:668698.
Score: 0.060
-
Stay-At-Home Orders Are Associated With Emergence of Novel SARS-CoV-2 Variants. Cureus. 2021 Mar 11; 13(3):e13819.
Score: 0.058